HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

TA I-95

for treatment of primary liver cancer; structure in first source

Also Known As:

N-(4-(4-((5-(2-methoxyethoxy)pyrazine-2-yl)thio)-2,6-dimethylphenyl)thiazol-2-yl)isonicotinamide; TAI-95

Networked: 2 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 4 or More Rings Heterocyclic Compounds
    - TA I-95: 2

Experts

1.	Chang, Jia-Ming: 2 articles (09/2014 - 06/2014)
2.	Chuang, Shih-Hsien: 2 articles (09/2014 - 06/2014)
3.	Huang, Jiann-Jyh: 2 articles (09/2014 - 06/2014)
4.	Huang, Lynn Y L: 2 articles (09/2014 - 06/2014)
5.	Kao, Kuo-Jang: 2 articles (09/2014 - 06/2014)
6.	Lau, Gillian M G: 2 articles (09/2014 - 06/2014)
7.	Lau, Johnson Y N: 2 articles (09/2014 - 06/2014)
8.	Lee, Ying-Shuan: 2 articles (09/2014 - 06/2014)
9.	Lin, Her-Sheng: 2 articles (09/2014 - 06/2014)
10.	Tsai, Pei-Yi: 2 articles (09/2014 - 06/2014)

Related Diseases

1.	Neoplasms (Cancer) 06/01/2014 - "This study highlights the potential of the novel anticancer compound TAI-95 in difficult-to-treat breast cancers." 06/01/2014 - "TAI-95 demonstrates strong inhibition of in vivo tumor growth of breast cancer model when administered orally, without inducing weight loss or other obvious toxicity. " 09/01/2014 - "TAI-95 showed synergistic activity in selected cancer cell lines with doxorubicin, paclitaxel, and topotecan, but not with sorafenib. "
2.	Liver Neoplasms (Liver Cancer) 09/01/2014 - "The purpose of this study was to evaluate the potential of a Hec1 inhibitor, TAI-95, as a treatment for primary liver cancer. " 09/01/2014 - "In vitro growth inhibition results showed that TAI-95 has excellent potency on a wide range of primary liver cancer cell lines (hepatoblastoma or hepatocellular carcinoma) (GI(50) 30-70 nM), which was superior to sorafenib and other cytotoxic agents. "
3.	Hepatoblastoma 09/01/2014 - "In vitro growth inhibition results showed that TAI-95 has excellent potency on a wide range of primary liver cancer cell lines (hepatoblastoma or hepatocellular carcinoma) (GI(50) 30-70 nM), which was superior to sorafenib and other cytotoxic agents. "
4.	Weight Loss (Weight Reduction) 06/01/2014 - "TAI-95 demonstrates strong inhibition of in vivo tumor growth of breast cancer model when administered orally, without inducing weight loss or other obvious toxicity. "
5.	Hepatocellular Carcinoma (Hepatoma) 09/01/2014 - "In vitro growth inhibition results showed that TAI-95 has excellent potency on a wide range of primary liver cancer cell lines (hepatoblastoma or hepatocellular carcinoma) (GI(50) 30-70 nM), which was superior to sorafenib and other cytotoxic agents. "

Related Drugs and Biologics

1.	Cytotoxins (Cytolysins)
2.	Topotecan (Hycamtin)
3.	Paclitaxel (Taxol)
4.	Doxorubicin (Adriamycin)
5.	Sorafenib (BAY 43-9006)